7 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $26.57, a high estimate of $31.00, and a low estimate of $20.00. A decline of 15.38% from the prior average price target is evident in the current average.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Law | Goldman Sachs | Announces | Buy | $23.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Lowers | Buy | $27.00 | $37.00 |
| Leland Gershell | Oppenheimer | Lowers | Outperform | $31.00 | $36.00 |
| Kalpit Patel | B. Riley Securities | Lowers | Neutral | $20.00 | $25.00 |
| Serge Belanger | Needham | Maintains | Buy | $30.00 | - |
| Kalpit Patel | B. Riley Securities | Lowers | Buy | $25.00 | $29.00 |
| Serge Belanger | Needham | Maintains | Buy | $30.00 | $30.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viridian Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Viridian Therapeutics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Viridian Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Viridian Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Viridian Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Viridian Therapeutics's Background
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
A Deep Dive into Viridian Therapeutics's Financials
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3 months period, Viridian Therapeutics faced challenges, resulting in a decline of approximately -26.53% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -67419.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Viridian Therapeutics's ROE excels beyond industry benchmarks, reaching -15.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Viridian Therapeutics's ROA excels beyond industry benchmarks, reaching -8.66%. This signifies efficient management of assets and strong financial health.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.